COVID-19 MANAGEMENT PROTOCOL Developed and updated by Paul Marik, MD Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School, Norfolk, VA
Preliminary data suggests that chloroquine and hydroxychloroquine decrease the duration of viral shedding. In addition, chloroquine has favorable immunomodulating properties including inhibition of PAI-1 expression. These agents are now FDA approved for the treatment of COVID19. These agents (if available) could be used to mitigate/curtail the spread of this virus and could be used in elderly patients with comorbidities at risk of progression and death. Zinc (Zn++) inhibits viral RNA dependent RNA polymerase (replicase). Chloroquine and hydroxychloroquine are potent Zn ionophores that increase intracellular Zn concentrations
https://www.inciid.org/sites/default...20-revised.pdf